Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients’ biofluids: Potential role in disease diagnosis and management
Ver/ Abrir
Impacto
Scholar |
Otros documentos de la autoría: Tomás Pérez, Sarai; Oto, Julia; AGHABABYAN, KRISTINA; Herranz, Raquel; Cuadros Lozano, Aitor; González Cantó, Eva; Mc Cormack, Bárbara Andrea; Arrés, Judith; Castano, Maria; Cana, Fernando; Martínez Fernández, Laura; Santonja, Núria; Ramírez, Rocío; Herreros Pomares, Alejandro; Cañete Mota, Sarai; Llueca, Antoni; Marí-Alexandre, Josep; Medina, Pilar; Gilabert-Estellés, Juan
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients’ biofluids: Potential role in disease diagnosis and managementAutoría
Fecha de publicación
2023Editor
Frontiers MediaISSN
1664-3224Cita bibliográfica
Tomás-Pérez S, Oto J, Aghababyan C, Herranz R, Cuadros-Lozano A, González-Cantó E, Mc Cormack B, Arrés J, Castaño M, Cana F, Martínez-Fernández L, Santonja N, Ramírez R, Herreros-Pomares A, Cañete-Mota S, Llueca A, Marí-Alexandre J, Medina P and Gilabert-Estellés J (2023) Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients’ biofluids: Potential role in disease diagnosis and management. Front. Immunol. 14:1111344. doi: 10.3389/fimmu.2023.1111344Tipo de documento
info:eu-repo/semantics/articleVersión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Introduction: High-grade serous ovarian cancer (HGSOC) is the second most frequent gynecological malignancy but the most lethal, partially due to the spread of the disease through the peritoneal cavity. Recent evidence ... [+]
Introduction: High-grade serous ovarian cancer (HGSOC) is the second most frequent gynecological malignancy but the most lethal, partially due to the spread of the disease through the peritoneal cavity. Recent evidence has shown that, apart from their role in immune defense through phagocytosis and degranulation, neutrophils are able to participate in cancer progression through the release of neutrophil extracellular traps (NETs) in a process called NETosis. NETs are composed of DNA, histones, calprotectin, myeloperoxidase (MPO) and elastase and the NETosis process has been proposed as a pre-requisite for the establishment of omental metastases in early stages of HGSOC. Nevertheless, its role in advanced stages remains to be elucidated. Therefore, our principal aim is to characterize a NETosis biomarker profile in biofluids from patients with advanced HGSOC and control women.
Methods: Specifically, five biomarkers of NETosis (cell-free DNA (cfDNA), nucleosomes, citrullinated histone 3 (citH3), calprotectin and MPO) were quantified in plasma and peritoneal fluid (PF) samples from patients (n=45) and control women (n=40).
Results: Our results showed that HGSOC patients presented a higher concentration of cfDNA, citH3 and calprotectin in plasma and of all five NETosis biomarkers in PF than control women. Moreover, these biomarkers showed a strong ability to differentiate the two clinical groups. Interestingly, neoadjuvant treatment (NT) seemed to reduce NETosis biomarkers mainly systemically (plasma) compared to the tumor environment (PF).
Discussion: In conclusion, NETosis biomarkers are present in the tumor environment of patients with advanced HGSOC, which might contribute to the progression of the disease. Besides, plasma cfDNA and calprotectin could represent minimally invasive surrogate biomarkers for HGSOC. Finally, NT modifies NETosis biomarkers levels mainly at the systemic level. [-]
Publicado en
Frontiers in Immunology 14:1111344Entidad financiadora
Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional | Generalitat Valenciana | Sociedad de Obstetricia y Ginecología de la Comunidad Valenciana | Fundación para la Investigación del Hospital General Universitario de Valencia | Sociedad Española de Trombosis y Hemostasia
Código del proyecto o subvención
PI17/01945 | PI17/00495 | PI20/00075 | PI22/01872 | GV/2020/200 | Prize SOGCV 2019 | Prize FIHGUV 2019 | Prize FIHGUV 2020 | Prize FIHGUV 2021 | ACIF/2020/216 | FI21/00171
Derechos de acceso
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- MED_Articles [641]